Geomedical Kft.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department conducts studies aimed at improving outcomes for patients with heart failure, reducing risk in atherosclerotic cardiovascular disease, and managing hypertension. Research includes therapies that target lipoprotein(a) and strategies to prevent major adverse cardiovascular events.
- Heart failure with preserved or mildly reduced ejection fraction
- Atherosclerotic cardiovascular disease prevention
- Hypertension and cardiovascular risk management
- Lipoprotein(a) reduction therapies
- Major adverse cardiovascular events (MACE) prevention
Geomedical Kft. collaborates with leading cardiology units in Budapest to advance treatment options for these conditions.
Digestive System Diseases
Clinical investigations focus on inflammatory bowel conditions such as Crohn's disease and ulcerative colitis, evaluating both induction and maintenance approaches to achieve remission and improve quality of life.
- Induction therapy for moderate to severe Crohn's disease
- Maintenance strategies for ulcerative colitis
- Novel oral agents for inflammatory bowel disease
- Biologic alternatives for refractory IBD
- Patient‑reported outcome measures in IBD
The site’s gastroenterology team leverages its expertise to test new therapeutic options for these chronic gastrointestinal disorders.
Immune System Diseases
Trials address immune‑mediated skin disorders, including atopic dermatitis, chronic spontaneous urticaria, and chronic pruritus of unknown origin, seeking effective and safe treatments for patients who have limited options.
- Targeted therapy for atopic dermatitis
- Management of chronic spontaneous urticaria
- Treatment of chronic pruritus of unknown origin
- Immune modulation in skin disease
- Safety of topical JAK inhibitors in youth
Geomedical Kft.’s immunology research integrates dermatology and systemic approaches to broaden therapeutic choices.
Nervous System Diseases
The site evaluates combination therapies for diabetic sensorimotor polyneuropathy, aiming to reduce neuropathic pain and improve functional outcomes for patients with diabetes‑related nerve damage.
- Combination therapy for diabetic neuropathy
- Pain reduction strategies in DSPN
- Functional outcomes in peripheral neuropathy
- Quality of life assessments in neuropathic patients
- Safety of multi‑modal treatment approaches
The neurologic research program collaborates with endocrinology specialists to address the complex needs of this population.
Nutritional and Metabolic Diseases
Studies explore integrated interventions for type 2 diabetes, obesity, and related metabolic risk factors, including the use of adjunctive agents with established glucose‑lowering medications.
- Adjunctive therapy with empagliflozin
- Weight management in heart failure patients
- Blood pressure control in diabetic populations
- Metabolic risk reduction strategies
- Integrated cardiovascular‑metabolic interventions
Geomedical Kft. leverages its metabolic clinic to test therapies that address both glycemic control and cardiovascular health.
Skin and Connective Tissue Diseases
Research includes trials for patients with moderate atopic dermatitis and severe itch, evaluating topical and systemic agents that aim to provide rapid symptom relief and long‑term disease control.
- Topical JAK inhibitor trials in adolescents
- Systemic therapy for severe eczema
- Itch reduction outcomes
- Safety of biologics in pediatric skin disease
- Long‑term efficacy of new dermal agents
The dermatology division at Geomedical Kft. focuses on translating novel mechanisms into practical treatments for patients.
Immune System Phenomena
Investigations into fundamental immune system phenomena support the development of cytokine‑targeted therapies and biomarker‑driven approaches across multiple disease categories.
- Cytokine blockade studies
- Biomarker identification in inflammatory disorders
- Immune response profiling
- Mechanistic studies of novel immunomodulators
- Translational immunology approaches
This foundational work underpins many of the site’s therapeutic programs and fosters collaborations with academic partners.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Geomedical Kft.
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants with Moderate-to-Severe Active Ulcerative Colitis. | Xencor Inc. | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 4 | Unknown | 2026-03-02 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.